A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)

Project: Research project

Project Details

StatusActive
Effective start/end date7/22/25 → 7/21/29

Funding

  • Dimerix Bioscience Pty Ltd ( Award # ): $26,545.00